Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement

Fig. 2

The routine protocol for ROS1 arrangements detection in NSCLC. IHC with D4D6 mAb can be preliminary screening tool for ROS1 rearrangement detection in NSCLC, and the IHC cutoff value should be set at 2–3+ cytoplasmic reactivity with diffuse (≥60 % of the tumor cells) distribution or an H-score ≥150; FISH and qRT-PCR should be used as the secondary confirmation in the cases with weak of focal IHC staining

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us